key: cord-0725197-e1ov774e
authors: Nanes, Benjamin A.
title: Reply to Research Letter
date: 2020-07-29
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.07.101
sha: 918a7ee25364bc54ddf8dd9794643280a33fa800
doc_id: 725197
cord_uid: e1ov774e

nan

In light of the current COVID-19 pandemic, scientists have debated the safety of immunosuppressive biologic therapies. We read with interest the letter by Wan et al, (1) "The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decisionmaking during the COVID-19 pandemic." We agree that caution should be used when exposing patients to systemic biologic agents in the setting of, not only COVID-19, but any acute or chronic infection, as Kaushik and Lebwohl(2) have previously emphasized.

In the authors' analysis, ixekizumab treatment groups did not report a significantly increased rate of respiratory tract infections (RTI). Despite an elevated rate of RTIs in the brodalumab and secukinumab treatment groups, the study included oropharyngitis, oropharyngeal pain and pharyngolaryngeal pain in their definition of RTI. Interleukin-17 (IL-17) are known to be associated with monilial infections(3), therefore thrush and esophagitis could potentially explain these increased rates and should have been excluded from the analysis. Furthermore, the rate of infection was higher in the placebo group in some studies. For example, the AMAGINE-2 trial reported an increased rate of upper respiratory tract infection (URTI) and rhinitis (7.44% and 0.65% in placebo groups vs. 5.39% and 0.33 in treatment groups, respectively). Similarly, the AMAGINE-3 trial reporting increased rates of nasopharyngitis and influenza (5.11% and 1.92% in the placebo groups vs. 4.97% and 1.28% in the brodalumab treatment groups, respectively). Placebo groups also lead to increased rates of nasopharyngitis (8.47%

vs. 5.08%), URTIs (1.69% vs. 0%) and nasal congestion (1.69% vs. 0%) when compared to treatment groups during the FEATURE trial. We realize that data can be included or excluded to display a certain desired outcome and hope such findings do not discourage clinicians from treating patients with the most efficacious biologic therapies available.

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathwayinhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections

Interleukin 17-A inhibition in the treatment of psoriasis